Healthcare Review: Rosetta Genomics, Endo International, Auxilium Pharmaceuticals, Agenus, BioDelivery Sciences Print E-mail
By Staff and Wire Reports   
Thursday, 26 June 2014 13:40
U.S. stocks fell on Thursday following comments from a top Federal Reserve official that interest rate increases should come sooner rather than later. St. Louis Fed President James Bullard said the U.S. jobless rate will fall below 6 percent and inflation looks likely to rise back to 2 percent later this year, putting the economy closer to normal than most realize. Bullard is non-voting member of the FOMC. Financial stocks were among the day's top decliners after New York State's attorney general filed a securities fraud lawsuit against Barclays, accusing the British bank of giving an unfair edge in the United States to high-frequency trading clients.

Rosetta Genomics ($ROSG) receives a Notice of Allowance from the USPTO for its patent application entitled "Compositions and Methods for Prognosis and Treatment of Prostate Cancer." The patent (No. 13/390,995) claims cover the expression of miR-205 as an indicator of good prognosis and relates to methods and kits for prognosis of prostate cancer.

Endo International ($ENDP) prices its private offering of $750M aggregate principal amount senior notes due January 2023 at 5.375%. The notes will be unsecured unsubordinated obligations of Endo Finance LLC and Endo Finco Inc. and will be guaranteed by Endo Limited, a wholly-owned subsidiary of Endo, and certain of Endo Limited's direct and indirect subsidiaries.

Auxilium Pharmaceuticals ($AUXL) and Canadian biotech QLT Inc. enter into a definitive agreement to merge. Under the terms of the agreement, QLT will remain incorporated in British Columbia and will be renamed "New Auxilium." Current AUXL shareholders will be receive 3.1359 QLT shares for each AUXL share. AUXL shareholders will own ~76% of the combined entity and QLT shareholders will own ~24%.

In an 80-patient randomized double-blind Phase 2 clinical trial evaluating Agenus' (AGEN) HerpV synthetic vaccine candidate for the treatment of genital Herpes Simplex Virus-2 (HSV-2), more than half of the 70 patients who received the vaccine developed a robust anti-HSV cytotoxic T-cell immune response. In this group of patients there was a statistically significant 75% reduction in viral load. This degree of reduction can potentially reduce the incidence and severity of herpetic outbreaks and a reduction in viral transmission.

BioDelivery Sciences ($BDSI) completes enrollment of its 140-patient 12-week double-blind Phase 3 clinical trial to evaluate Clonidine Topical Gel as a treatment for painful diabetic neuropathy (PDN). This is the first of two Phase 3 studies that will be required for an NDA submission for the Fast Track-designated product. The second trial will commence in Q1 2015.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter